Stage IVB, recurrent or persistant cervical cancer
Conditions
Interventions
Paclitaxel 175mg/m2 day1 Carboplatin AUC=5 day1 Bevacizumab 15mg/kg day1 tri-weekly
Sponsors
Japan Gynecologic Oncology Group:JGOG
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements. 2.More than 20 years old 3.ECOG Performance Status: 0-2 4.Life expectancy of >= 90 days 5.Histologically confirmed cervical cancer by histopathologic examination of uterine cervix 6.Patients with a diagnosis of confirmed cervical cancer such as squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma 7.Patients can be included if they have measurable diseases. 8.Adequate following organ function.
Exclusion criteria
Exclusion criteria: 1.Patient who has received any cheotherapy except for CCRT 2.Patient with perforation of the digestive tract and severe fistula within 6 months before registration 3.Patient with a history of hypersensitivity to the drug used in combination to bevacizumab 4.Patient with active infection at registration 5. Patient with uncontrolled hypertension at registration 6.Patient suspected or diagnosed as arterial thromboembolism (cerebral infarction, myocardial infarction, etc.) at registration 7.Patient who is judged inappropriate to participate in this study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival: PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Response Rate: ORR Overall Survival: OS Time to Treatment Failure: TTF Safety | — |
Countries
Japan
Contacts
Public ContactMaki Matoda, M.D.
Cancer Institute Hospital Department of Gynecology
Outcome results
None listed